← Back to headlines
Kiniksa Projects 2026 Revenue Guidance and Advances KPL-387 to Phase III
Kiniksa Pharmaceuticals projects 2026 revenue guidance between $980 million and $995 million while advancing its drug candidate KPL-387 into Phase III PASTORALE trials.
28 Jul, 14:25 — 28 Jul, 14:25
Sources
Showing 1 of 1 sources
